Medmain
Medmain Inc. is a Fukuoka, Japan–based healthcare technology company developing PidPort, an AI-powered cloud platform for digital pathology that provides AI-based cancer screening, telepathology, and slide image storage for hospitals and medical institutions, distributed in Japan via PSP Corporation and internationally through channel partners.
- Company typePrivate
- Founded2018
- HeadquartersFukuoka, Japan
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Medmain does
Medmain Inc. is a Japanese healthcare technology company founded in January 2018 in Fukuoka, Japan, that develops and operates PidPort, an AI-powered cloud platform for digital pathology. The platform combines three integrated modules: deep learning–based AI analysis for pathological screening across multiple organs (stomach, colon, lung, breast, prostate, pancreas, skin), telepathology for remote pathological diagnosis via cloud networks, and cloud-based storage and management of digitized pathology specimens. The company's underlying technology uses proprietary transfer learning and weakly supervised learning to develop pathology AI models, with disclosed accuracy of ROC-AUC 0.94–0.99 across cancer detection tasks. Medmain also offers the Imaging Center service for physical-to-digital conversion of pathology slides and Medteria, a separate cloud service for medical students.
The company operates a subscription-based SaaS revenue model with no initial equipment fees, selling primarily through direct enterprise sales to hospitals and medical institutions, supplemented by channel partnerships. In Japan, distribution occurs via a capital and business alliance with PSP Corporation, which provides access to roughly 2,200 medical institutions and 22%+ of the Japanese PACS market. Internationally, Medmain has signed MOUs with major Vietnamese hospitals (Bach Mai, E Hospital, Thai Nguyen A, Ha Dong General) and partners with SMC Co., Ltd. for Asia distribution. The company has secured ISO/IEC 27001:2022 (November 2024), ISO 13485:2016 (January 2025), and a Japanese First-Class Marketing License for Medical Devices (July 2024). According to a February 2026 M&A report, Medmain was acquired by PSP Corporation.
Medmain firmographics
Firmographics- Name
- Medmain
- Legal name
- Medmain Inc.
- Website
- https://en.medmain.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Medmain Inc. is a Fukuoka, Japan–based healthcare technology company developing PidPort, an AI-powered cloud platform for digital pathology that provides AI-based cancer screening, telepathology, and slide image storage for hospitals and medical institutions, distributed in Japan via PSP Corporation and internationally through channel partners.
- Ownership category
- akta.pro rank
Medmain industry classification
Industry- Product category
- Digital Pathology Software
- NAICS
- Computer Systems Design and Related Services (54151)
- SIC
- Services-Medical Laboratories (8071), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Anatomic Pathology LIS & Digital Pathology Workflow (HLACAMAB)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
Keywords
Where Medmain is headquartered
LocationHeadquarters
- HQ city
- Fukuoka
- HQ country
- Japan
- HQ region
- Asia
Offices3 records
Markets served
Medmain business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- PidPort Subscription: Cloud-based SaaS subscription model for pathological image diagnosis platform. Access via web application without initial equipment fees. Revenue generated from subscription fees for AI analysis, telepathology, and cloud storage services.
- Imaging Center Services: High-quality digital imaging services for pathological tissue specimens using on-site scanners, with secure cloud-based storage. Revenue from digitization and storage services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Cloud-based subscription with no initial equipment fees |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Medmain product offering
Product offeringCore offering
Medmain develops and operates PidPort, an AI-powered cloud platform for digital pathology support that uses proprietary deep learning to perform super-precise, instantaneous screening of pathologic tissue and cells across multiple organs (stomach, colon, lung, breast, prostate, pancreas, skin). PidPort combines three integrated capabilities — AI-based pathological screening, telepathology (remote pathological diagnosis over a global cloud network), and cloud-based storage and management of digitized pathologic specimens. The offering is delivered as a SaaS subscription accessible via web application with no upfront equipment fees, and is supported by an Imaging Center service that digitizes histopathological specimens on site.
Product overview
Medmain operates as a medical software company offering a unified product ecosystem centered on PidPort, an AI-powered cloud platform for digital pathology. The core PidPort platform combines three integrated modules: AI Analysis (deep learning-based pathological screening for multiple organ cancer detection), Telepathology (globally-linked remote pathological diagnosis via cloud networks), and Cloud Storage (digitization and management of pathologic specimen images). The Imaging Center service provides the digitization infrastructure that feeds into PidPort's cloud platform. Additionally, Medmain developed Medteria as a separate cloud service for medical education. The company has also developed specialized AI models for specific applications such as Ki-67 labeling index measurement in immunohistochemistry specimens.
Differentiator
Problem solved
Functional benefit
Brands
- PidPort: AI-powered cloud system for digital pathology support with features including AI analysis, telepathology, and cloud storage for pathological specimens
- Medteria
- Imaging Center
Products and services
- PidPort Digital Pathology Platform AI-powered cloud platform for digital pathology that delivers super-precise, instantaneous AI-based pathological screening of tissue and cells, telepathology-enabled remote pathological diagnosis, and cloud-based storage and management of digitized pathologic specimens. Built for hospitals, medical institutions, and pathology departments.
- Imaging Center High-quality digitization service for histopathological tissue specimens using specialized scanners, with secure cloud-based storage and web-based viewing platform for pathologic image management. Designed for hospitals and pathology labs that need to convert physical specimens into high-quality digital images and feed them into PidPort's cloud platform.
- Medteria Tailored cloud service for medical students that organizes and manages study materials to support efficient access to required learning information. Used by medical schools in Japan as an education technology platform.
- Ki-67 AI for Immunohistochemistry Analysis AI model that automatically detects Ki-67 positive and negative cells by identifying cell nuclei and performing cell-level classification on whole-slide immunohistochemistry images, then calculates the labeling index to support cancer prognosis assessment.
Quantifiable outcome
- ROC-AUC up to 0.99 for various cancer detection tasks including gastric, colonic, and lung cancer classification
- +3 more outcomes
Companies that use Medmain
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Medmain technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Medmain partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered major and core.
- Ha Dong General HospitalmajorLevel I municipal hospital in Hanoi implementing PidPort for research and pilot testing. MOU signed with SMC and hospital with representatives from Embassy of Japan in Vietnam present.
- Bach Mai HospitalcoreMOU for comprehensive cooperation in digital pathology support and utilization of medical AI in Vietnam. Medmain will lead introduction, pilot implementation, and nationwide deployment of PidPort across Vietnamese medical institutions.
- E HospitalcoreMOU partner for digital transformation of pathology and AI cancer diagnostics. E Hospital is a major medical institution under Vietnamese Ministry of Health with focus on digitalization.
- Thai Nguyen A HospitalcoreMOU partner for digital pathology and AI adoption in cytology, histopathology, and lesion classification. Regional hub for medical care and education in northern Vietnam.
- SMC Co., Ltd. (Medical Tourism Japan Division)corePartnership agreement signed to promote research and application of AI in pathological diagnosis in Vietnam. SMC supports medical tourism and overseas expansion of Japanese medical technologies.
- Japan Innovation Campus (METI)majorSelected as coworking member of Japan's new startup base in Silicon Valley established by Ministry of Economy, Trade and Industry. Provides access to local VCs, accelerators, and Stanford/UC Berkeley resources for US market expansion.
- U.S. Market Gateway Accelerator for BioSciences and MedTechmajorSelected for WorldUpstart accelerator program sponsored by US Market Gateway, providing support for business development in the US market.
- PSP CorporationcoreCapital and business alliance partner with ~2,200 medical institution customers and 22%+ market share in Japan PACS market. PSP integrates Medmain's pathology AI into its infrastructure platforms (NOBORI cloud storage, ICHIGO remote image diagnosis) and sells Medmain products to its customer base.
Scale indicators6 records
Recent moves9 records
Expansion highlights6 records
Medmain competitors and assessment
Company assessmentDirect peers
- Paige.AI: US-based pathology AI company with the first FDA-authorized AI product in pathology (Prostate). Directly comparable to Medmain in applying deep learning to whole slide images for cancer detection and offering enterprise pathology AI solutions to hospitals.
- PathAI: Boston-based AI pathology company offering both diagnostic AI products and biopharma research services. Closely comparable to Medmain's PidPort in using deep learning on histopathology images to support pathologist decision-making across multiple cancer types.
- Ibex Medical Analytics: Israel-based pathology AI platform deployed across multiple hospital systems in Europe and the US for cancer detection across breast, prostate, and gastrointestinal tissues. Directly competes with PidPort as an enterprise AI pathology screening and triage platform.
- Proscia: US-based digital pathology platform offering Concentriq, a cloud-based workflow and AI platform for pathology laboratories. Comparable to Medmain's PidPort in providing cloud-hosted pathology image management combined with AI-based analysis tools.
- Owkin: France-based AI biotech building pathology and multimodal AI models for cancer research and diagnostics, including the Klarity digital pathology product. Comparable to Medmain for AI-driven histopathology analysis serving hospitals and research institutions.
Emerging players
- Aiosyn: Netherlands-based pathology AI company developing deep learning models for kidney and prostate biopsy assessment. Emerging player with partial overlap to Medmain's organ-specific pathology AI focus and ISO 13485-style regulatory positioning.
Broad incumbents
- Hamamatsu Photonics: Japan-headquartered global leader in whole-slide imaging scanners (NanoZoomer) and a major participant in digital pathology infrastructure. Comparable to Medmain as part of the same Japan digital pathology ecosystem and potential imaging input source for PidPort's cloud workflow.
- Philips (Digital Pathology): Global medtech incumbent whose IntelliSite Pathology Solution is one of the most widely deployed whole-slide imaging and pathology workflow platforms. Competes with PidPort at the enterprise hospital level as a broader imaging and informatics portfolio vendor.
- Leica Biosystems: Global pathology vendor offering Aperio digital pathology scanners and image management systems used by hospitals and research institutions. Overlaps with Medmain as a digital pathology workflow incumbent with broader hardware and software stack.
- Sakura Finetek: Japan-headquartered histology and pathology equipment vendor with global reach in tissue processing, embedding, and slide preparation systems. Comparable as part of the broader pathology workflow stack where Medmain's Imaging Center and AI analysis plug in.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Medmain social profiles
Digital presenceMedmain compliance and trust
Trust signalCompliance2 records
Medmain financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medmain leadership team
Management profileNumber of profiles
Profiles5 records
Medmain subsidiaries and ownership
Company hierarchySubsidiaries1 record
Medmain funding detail
Funding detailFunding overview
Funding rounds6 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medmain M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medmain
What does Medmain do?
Medmain develops and operates PidPort, an AI-powered cloud platform for digital pathology support that uses proprietary deep learning to perform super-precise, instantaneous screening of pathologic tissue and cells across multiple organs (stomach, colon, lung, breast, prostate, pancreas, skin). PidPort combines three integrated capabilities — AI-based pathological screening, telepathology (remote pathological diagnosis over a global cloud network), and cloud-based storage and management of digitized pathologic specimens. The offering is delivered as a SaaS subscription accessible via web application with no upfront equipment fees, and is supported by an Imaging Center service that digitizes histopathological specimens on site.
Is Medmain a public or private company?
Medmain is a private company. It is classified as corporate owned and is currently acquired.
When was Medmain founded?
Medmain was founded in 2018. It employs 11 to 50 people.
Where is Medmain based?
Medmain is headquartered in Fukuoka, Japan, in the Asia region.
How does Medmain make money?
Two revenue lines are on record. PidPort Subscription is the primary driver. The others are imaging Center Services.
Who are Medmain's main competitors?
Direct peers on record are Paige.AI, PathAI, Ibex Medical Analytics, Proscia and Owkin. Aiosyn is listed as an emerging player. Broad incumbents are Hamamatsu Photonics, Philips (Digital Pathology), Leica Biosystems and Sakura Finetek.
Does Medmain have an API?
No public API is recorded for Medmain.
What industry is Medmain in?
Medmain's product category is Digital Pathology Software. Its primary akta.pro industry code is HLACAMAB, Anatomic Pathology LIS & Digital Pathology Workflow, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 54151 and its SIC code is 8071.